Long-term Weight Loss With Sibutramine: A Randomized Controlled Trial
The DOI matches its Crossref record; 20 of the 20 references it cites were found in a registry or an index.
Abstract
CONTEXT: Treatment of obesity requires long-term therapy, which can be hampered by difficulties in achieving patient compliance. The effectiveness of sibutramine hydrochloride in treating obesity has been shown in randomized controlled trials. OBJECTIVE: To compare the effectiveness of 2 distinct sibutramine regimens with each other and with placebo for weight reduction among obese persons. DESIGN: Randomized, double-blind, parallel-group placebo-controlled trial from April 1997 to September 1998. SETTING: One hundred eight private practices and 3 outpatient departments of university hospitals in Germany. PATIENTS: A total of 1102 obese adults (body mass index, 30-40 kg/m(2)) entered the 4-week open-label run-in period with 15 mg/d of sibutramine, 1001 of whom had weight loss of at least 2% or 2 kg were randomized into the 44-week randomized treatment period. INTERVENTIONS: Patients were randomly assigned to receive 15 mg/d of sibutramine continuously throughout weeks 1-48 (n = 405); 15 mg/d of sibutramine intermittently during weeks 1-12, 19-30, and 37-48, with placebo during all other weeks (n = 395); or placebo for weeks 5-48 (n = 201). MAIN OUTCOME MEASURE: Weight loss during the randomized treatment period, compared among all 3 groups. RESULTS: Mean weight loss in the intention-to-treat population during the 44-week randomized treatment period was 3.8 kg (4.0%) in patients receiving continuous therapy (95% confidence interval [CI], - 4.42 to - 3.20 kg) and was 3.3 kg (3.5%) in patients receiving intermittent therapy (95% CI, - 3.96 to - 2.66 kg), vs a mean weight gain of 0.2 kg (0.2%) (95% CI, - 0.60 to 0.94 kg) in patients receiving placebo. Therapeutic equivalence of the 2 active treatments could be shown. Although there was a greater weight loss in the continuous than in the intermittent group, this difference was nonsignificant (P =.28) and the 95% CIs were within the predefined range of therapeutic equivalence-0 +/-1.5 kg (-1.37 to 0.28 for the intent-to-treat population). Overall weight loss during the 48-week period was 7.9 kg and 7.8 kg in the continuous and intermittent groups, respectively, but was 3.8 kg in the sibutramine run-in placebo group. Waist circumference reduction, triglyceride levels, and high-density lipoprotein cholesterol concentrations were also positively influenced by sibutramine treatment. Systolic and diastolic blood pressures were stable across all 3 groups. Overall, adverse events occurred at similar frequencies across all treatment groups, but the proportion was lowest in the group receiving intermittent therapy. CONCLUSIONS: Sibutramine, administered for 48 weeks to a typically obese population, results in clinically relevant weight loss compared with placebo. Regarding effectiveness, continuous and intermittent sibutramine therapies are equivalent and the safety profiles for both treatments are comparable.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
(1999) · Journal of Hypertension · doi:10.1097/00004872-199917020-00001 · Cited by 3,695
Rubins, H. B., Robins, S. J., Collins, D., Fye, C. L., Anderson, J. W., Elam, M. B., Faas, F. H., Linares, E., Schaefer, E. J., Schectman, G., et al. (1999) · New England Journal of Medicine · doi:10.1056/nejm199908053410604 · Cited by 3,439
Kuczmarski, R. J. (1994) · JAMA · doi:10.1001/jama.272.3.205 · Cited by 2,362
Sjöström, L., Rissanen, A., Andersen, T., Boldrin, M., Golay, A., Koppeschaar, H. P., & Krempf, M. (1998) · The Lancet · doi:10.1016/s0140-6736(97)11509-4 · Cited by 1,237
Davidson, M. H., Hauptman, J., DiGirolamo, M., Foreyt, J. P., Halsted, C. H., Heber, D., Heimburger, D. C., Lucas, C. P., Robbins, D. C., Chung, J., et al. (1999) · JAMA · doi:10.1001/jama.281.3.235 · Cited by 947
Assmann, G., & Schulte, H. (1992) · The American Journal of Cardiology · doi:10.1016/0002-9149(92)90550-i · Cited by 872 · cited 2×
“This therapeutic effect demonstrates the benefits of drug therapy by improving lipid metabolism disorders that are frequently present in patientswithobesityconstitutinganatherogenic risk factor.(32) Weight loss is usually associated with a decrease in blood pressure.”
BackgroundEffect of sibutramine on weight maintenance after weight loss: a randomised trial
James, W. P. T., Astrup, A., Finer, N., Hilsted, J., Kopelman, P., Rössner, S., Saris, W. H. M., & Gaal, L. F. V. (2000) · The Lancet · doi:10.1016/s0140-6736(00)03491-7 · Cited by 817
Wood, P. D., Stefanick, M. L., Dreon, D. M., Frey-Hewitt, B., Garay, S. C., Williams, P. T., Superko, H. R., Fortmann, S. P., Albers, J. J., Vranizan, K. M., et al. (1988) · New England Journal of Medicine · doi:10.1056/nejm198811033191801 · Cited by 675 · cited 1×
“The decline and increase in triglyceride and HDL-cholesterol levels observed in this study are not drugspecific effects but are commonly observed following weight loss.(34) It has been shown that a decrease in triglyceride levels and an increase in HDLcholesterol may reduce the risk of cardiovascular disease.”
BackgroundWilliamson, D. F., Pamuk, E., Thun, M., Flanders, D., Byers, T., & Heath, C. (1995) · American Journal of Epidemiology · doi:10.1093/oxfordjournals.aje.a117386 · Cited by 527
Sibutramine Produces Dose‐Related Weight Loss
Bray, G. A., Blackburn, G. L., Ferguson, J. M., Greenway, F. L., Jain, A. K., Mendel, C. M., Mendels, J., Ryan, D. H., Schwartz, S. L., Scheinbaum, M. L., et al. (1999) · Obesity Research · doi:10.1002/j.1550-8528.1999.tb00701.x · Cited by 382
Apfelbaum, M., Vague, P., Ziegler, O., Hanotin, C., Thomas, F., & Leutenegger, E. (1999) · The American Journal of Medicine · doi:10.1016/s0002-9343(98)00411-2 · Cited by 345
(2014) · Handbook of Obesity -- Volume 1 · doi:10.1201/b16473-49 · Cited by 263
Sibutramine: A Review of its Contribution to the Management of Obesity
McNeely, W., & Goa, K. L. (1998) · Drugs · doi:10.2165/00003495-199856060-00019 · Cited by 219
A Double‐Blind Randomized Placebo‐Controlled Trial of Sibutramine
Bray, G. A., Ryan, D. H., Gordon, D., Heidingsfelder, S., Cerise, F., & Wilson, K. (1996) · Obesity Research · doi:10.1002/j.1550-8528.1996.tb00544.x · Cited by 187
Siöström, C. D., Lissner, L., & Siostrom, L. (1997) · Obesity Research · doi:10.1002/j.1550-8528.1997.tb00572.x · Cited by 179
Sibutramine--a review of clinical efficacy.
Lean, M. E. J. (1997) · PubMed · Cited by 157
Sibutramine: A Serotonin–Norepinephrine Reuptake-Inhibitor for the Treatment of Obesity
Luque, C. A., & Rey, J. A. (1999) · Annals of Pharmacotherapy · doi:10.1345/aph.18319 · Cited by 155
Sibutramine: A Novel New Agent for Obesity Treatment
Ryan, D. H., Kaiser, P., & Bray, G. A. (1995) · Obesity Research · doi:10.1002/j.1550-8528.1995.tb00227.x · Cited by 102
Futility and Avoidance: Medical Professionals in the Treatment of Obesity
Frank, A. (1993) · JAMA · doi:10.1001/jama.1993.03500160102041 · Cited by 92
Gaal, L. F. V., Wauters, M., PEIFFER, F. W., & Leeuw, I. H. D. (1998) · PubMed · Cited by 39
Cited by
Avenell, A., Broom, J., Brown, T., Poobalan, A., Aucott, L., Stearns, S., Smith, W., Jung, R., Campbell, M., & Grant, A. (2004) · Health Technology Assessment · doi:10.3310/hta8210 · Cited by 1,041
Klein, S., Burke, L. E., Bray, G. A., Blair, S., Allison, D. B., Pi-Sunyer, X., Hong, Y., & Eckel, R. H. (2004) · Circulation · doi:10.1161/01.cir.0000145546.97738.1e · Cited by 934
Villareal, D. T., Apovian, C. M., Kushner, R. F., & Klein, S. (2005) · The American Journal of Clinical Nutrition · doi:10.1093/ajcn/82.5.923 · Cited by 880
on behalf of the NN8022-1923 Investigators, Wadden, T. A., Hollander, P., Klein, S., Niswender, K., Woo, V, Hale, P. M., & Aronne, L. (2013) · International Journal of Obesity · doi:10.1038/ijo.2013.120 · Cited by 842
Meta-Analysis: Pharmacologic Treatment of Obesity
Li, Z., Maglione, M., Tu, W., Mojica, W., Arterburn, D., Shugarman, L. R., Hilton, L., Suttorp, M., Solomon, V., Shekelle, P. G., et al. (2005) · Annals of Internal Medicine · doi:10.7326/0003-4819-142-7-200504050-00012 · Cited by 774
Metadata
- Authors
- Wirth, A., & Krause, J.
- Venue
- JAMA
- Publisher
- American Medical Association (AMA)
- Published
- 2001-09-19
- Volume
- 286
- Issue
- 11
- Pages
- 1331
- ISSN
- 0002-9955 (ISSN-L)
- 0098-7484
- OpenAlex
- W2065517231
- Cited by
- 272
- References
- 20
- FWCI
- 19.56
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.